bilirubin
Small moleculeexperimental
Bilirubin (BR) is a red-orange compound that occurs as the reduction product of biliverdin, a breakdown product of heme. It's further broken down in the colon to urobilinogen, most of which becomes stercobilin, causing the brown color of feces. Some unconverted urobilinogen, metabolised to urobilin, provides the straw-yellow color in urine. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2007 (NCT00692510)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- BilirubinSupplementation
Bilirubin supplementation
Chemistry & pharmacology
Loading structure…
SMILES
C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O- Mol. weight
- 584.67 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBilirubin ↗
- ChEMBLCHEMBL501680 ↗
Also known as
- bilirubin
- bilirubin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00692510 | Phase 1 | Nov 1, 2007 | AstraZeneca, ICON |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 1 | 1 | 1 | 2007 |
| ICON | For profit | 1 | 0 | 1 | 2007 |
2 organizations
Page 1 / 1